Antibiotics | Susceptible | Resistant | ||
---|---|---|---|---|
Number | Rate (%) | Number | Rate (%) | |
Amikacin | 3 | 15.0% | 17 | 85.0% |
Ceftazidime | 0 | 0.0% | 20 | 100% |
Ciprofloxacin | 0 | 0.0% | 20 | 100% |
Levofloxacin | 0 | 0.0% | 20 | 100% |
Gentamicin | 0 | 0.0% | 20 | 100% |
Tobramycin | 3 | 15.0% | 17 | 85.0% |
Ceftriaxone | 0 | 0.0% | 20 | 100% |
Cefotaxime | 0 | 0.0% | 20 | 100% |
Cefepime | 0 | 0.0% | 20 | 100% |
Imipenem | 0 | 0.0% | 20 | 100% |
Meropenem | 0 | 0.0% | 20 | 100% |
Trimethoprim/sulfamethoxazole | 6 | 30.0% | 14 | 100% |
Piperacillin/tazobactam | 0 | 0.0% | 20 | 100% |
Tigecycline | 20 | 100% | 0 | 0.0% |
Polymyxin B | 20 | 100% | 0 | 0.0% |
Strain / Antibiotics | TAaba004 | TAaba012 |
---|---|---|
Amikacin | R | R |
Ceftazidime | R | R |
Ciprofloxacin | R | R |
Levofloxacin | R | R |
Gentamicin | R | R |
Tobramycin | R | R |
Ceftriaxone | R | R |
cefotaxime | R | R |
Cefepime | R | R |
Imipenem | R | R |
Meropenem | R | R |
Trimethoprim/sulfamethoxazole | R | R |
Piperacillin/tazobactam | R | R |
Tigecycline | S | S |
Polymyxin B | S | S |